816 related articles for article (PubMed ID: 22786606)
1. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
[TBL] [Abstract][Full Text] [Related]
2. Baseline [
Teng E; Manser PT; Sanabria Bohorquez S; Wildsmith KR; Pickthorn K; Baker SL; Ward M; Kerchner GA; Weimer RM
Alzheimers Res Ther; 2021 Dec; 13(1):196. PubMed ID: 34852837
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
[TBL] [Abstract][Full Text] [Related]
4. Left lateralized cerebral glucose metabolism declines in amyloid-β positive persons with mild cognitive impairment.
Weise CM; Chen K; Chen Y; Kuang X; Savage CR; Reiman EM;
Neuroimage Clin; 2018; 20():286-296. PubMed ID: 30101060
[TBL] [Abstract][Full Text] [Related]
5. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
6. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
[TBL] [Abstract][Full Text] [Related]
7. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
[TBL] [Abstract][Full Text] [Related]
9. Temporal Dynamics of β-Amyloid Accumulation in Aging and Alzheimer Disease.
Jagust WJ; Landau SM;
Neurology; 2021 Mar; 96(9):e1347-e1357. PubMed ID: 33408147
[TBL] [Abstract][Full Text] [Related]
10. Financial Management Skills in Aging, MCI and Dementia: Cross Sectional Relationship to 18F-Florbetapir PET Cortical β-amyloid Deposition.
Tolbert S; Liu Y; Hellegers C; Petrella JR; Weiner MW; Wong TZ; Murali Doraiswamy P
J Prev Alzheimers Dis; 2019; 6(4):274-282. PubMed ID: 31686100
[TBL] [Abstract][Full Text] [Related]
11. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
[TBL] [Abstract][Full Text] [Related]
12. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
[TBL] [Abstract][Full Text] [Related]
13. Florbetapir Regional Distribution in Cerebral Amyloid Angiopathy and Alzheimer's Disease: A PET Study.
Planton M; Saint-Aubert L; Raposo N; Payoux P; Salabert AS; Albucher JF; Olivot JM; Péran P; Pariente J
J Alzheimers Dis; 2020; 73(4):1607-1614. PubMed ID: 31958082
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic value of amyloid PET textural and shape features: comparison with classical semi-quantitative rating in 760 patients from the ADNI-2 database.
Ben Bouallègue F; Vauchot F; Mariano-Goulart D; Payoux P
Brain Imaging Behav; 2019 Feb; 13(1):111-125. PubMed ID: 29427064
[TBL] [Abstract][Full Text] [Related]
15. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal head-to-head comparison of
Chen CD; McCullough A; Gordon B; Joseph-Mathurin N; Flores S; McKay NS; Hobbs DA; Hornbeck R; Fagan AM; Cruchaga C; Goate AM; Perrin RJ; Wang G; Li Y; Shi X; Xiong C; Pontecorvo MJ; Klein G; Su Y; Klunk WE; Jack C; Koeppe R; Snider BJ; Berman SB; Roberson ED; Brosch J; Surti G; Jiménez-Velázquez IZ; Galasko D; Honig LS; Brooks WS; Clarnette R; Wallon D; Dubois B; Pariente J; Pasquier F; Sanchez-Valle R; Shcherbinin S; Higgins I; Tunali I; Masters CL; van Dyck CH; Masellis M; Hsiung R; Gauthier S; Salloway S; Clifford DB; Mills S; Supnet-Bell C; McDade E; Bateman RJ; Benzinger TLS;
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2669-2682. PubMed ID: 37017737
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of amyloid PET using
Matsuda H; Okita K; Motoi Y; Mizuno T; Ikeda M; Sanjo N; Murakami K; Kambe T; Takayama T; Yamada K; Suehiro T; Matsunaga K; Yokota T; Tateishi U; Shigemoto Y; Kimura Y; Chiba E; Kawashima T; Tomo Y; Tachimori H; Kimura Y; Sato N
Ann Nucl Med; 2022 Dec; 36(12):1039-1049. PubMed ID: 36194355
[TBL] [Abstract][Full Text] [Related]
18. Positive rate and quantification of amyloid pathology with [
He K; Li B; Huang L; Zhao J; Hua F; Wang T; Li J; Wang J; Huang Q; Chen K; Xu S; Ren S; Cai H; Jiang D; Hu J; Han X; Guan Y; Chen K; Guo Q; Xie F
Eur Radiol; 2024 May; 34(5):3331-3341. PubMed ID: 37889270
[TBL] [Abstract][Full Text] [Related]
19. Association of amyloid-β CSF/PET discordance and tau load 5 years later.
Reimand J; Collij L; Scheltens P; Bouwman F; Ossenkoppele R;
Neurology; 2020 Nov; 95(19):e2648-e2657. PubMed ID: 32913020
[TBL] [Abstract][Full Text] [Related]
20. Memory decline accompanies subthreshold amyloid accumulation.
Landau SM; Horng A; Jagust WJ;
Neurology; 2018 Apr; 90(17):e1452-e1460. PubMed ID: 29572282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
